olokizumab
Olokizumab (OKZ) sold under the name Artlegia, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis and COVID-19. It is a humanized monoclonal antibody against the interleukin-6 (IL-6). IL-6 is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases. Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. Olokizumab was developed by R-Pharm group, and was launched in 2020. — Wikipedia
Clinical trial activity
19 trials · 12 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2008 (NCT01276119)
Timeline
Indications
Mechanism of action
- Interleukin-6INHIBITOR
IL6 inhibitor
Binds to IL-6 at Site 3 and neutralizes biological activity through blocking hexamer (of two molecules each of IL6, IL6R and IL6ST/gp130) formation on the IL6ST/gp130 signaling axis.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOlokizumab ↗
- ChEMBLCHEMBL2109652 ↗
- ChEMBLCHEMBL1743050 ↗
Also known as
- cdp6038
- cdp 6038
- cdp-6038
- olokizumab
- olokizumab
- olokizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07206043 | Phase 1 | Dec 3, 2024 | R-Pharm |
| NCT06440746 | Phase 2/Phase 3 (Phase 3) | Aug 23, 2023 | Data Management 365 LLC, Exacte Labs LLC, Keystat, R-Pharm |
| NCT05187793 | Phase 3 | Jul 8, 2021 | R-Pharm |
| NCT04463251 | Phase 2 | Nov 1, 2020 | Cromos Pharma, LLC, Data Management 365 LLC, Keystat, K-Research, R-Pharm |
| NCT04452474 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | Covance, Cromos Pharma, LLC, R-Pharm |
| NCT04380519 | Phase 2/Phase 3 (Phase 3) | Apr 23, 2020 | R-Pharm |
| NCT04246762 | Phase 1 | Mar 1, 2020 | IQVIA, R-Pharm, Thermo Fisher Scientific |
| NCT03120949 | Phase 3 | Jun 1, 2017 | IQVIA, MENE Research, OCT Clinical Trials, R-Pharm |
| NCT02760433 | Phase 3 | Dec 1, 2016 | IQVIA, MENE Research, OCT Clinical Trials, R-Pharm |
| NCT02760407 | Phase 3 | May 1, 2016 | IQVIA, OCT Clinical Trials, R-Pharm |
| NCT02760368 | Phase 3 | May 1, 2016 | IQVIA, MENE Research, OCT Clinical Trials, R-Pharm |
| NCT01635621 | Phase 2 | Jun 1, 2012 | Hoosier Cancer Research Network |
| NCT01533714 | Phase 2 | Jan 1, 2012 | Hoosier Cancer Research Network |
| NCT01463059 | Phase 2 | Oct 1, 2011 | Hoosier Cancer Research Network |
| NCT01296711 | Phase 2 | Mar 1, 2011 | Hoosier Cancer Research Network |
| NCT01242488 | Phase 2 | Nov 1, 2010 | Hoosier Cancer Research Network |
| NCT01262794 | Phase 1 | Nov 1, 2010 | Hoosier Cancer Research Network |
| NCT01009242 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2009 | Hoosier Cancer Research Network |
| NCT01276119 | Phase 1 | Sep 1, 2008 | Hoosier Cancer Research Network |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| R-Pharm | For profit | 11 | 11 | 3 | 2016 |
| Hoosier Cancer Research Network | Academic/Hospital | 8 | 8 | 2 | 2008 |
| IQVIA | For profit | 5 | 0 | 2 | 2016 |
| OCT Clinical Trials | For profit | 4 | 0 | 1 | 2016 |
| MENE Research | For profit | 3 | 0 | 1 | 2016 |
| Cromos Pharma, LLC | For profit | 2 | 0 | 2 | 2020 |
| Data Management 365 LLC | For profit | 2 | 0 | 2 | 2020 |
| Keystat | For profit | 2 | 0 | 2 | 2020 |
| Covance | For profit | 1 | 0 | 1 | 2020 |
| Exacte Labs LLC | For profit | 1 | 0 | 1 | 2023 |
| K-Research | For profit | 1 | 0 | 1 | 2020 |
| Thermo Fisher Scientific | For profit | 1 | 0 | 1 | 2020 |